BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

...that the pharma gained under a 2009 deal with Oxford BioMedica. The products are StarGen (SAR422459...
...encoding MYO7A. Oxford said Sanofi confirmed it will continue its Phase I/II proof-of-concept study for StarGen...
...VIIA Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Business: Ophthalmology Shannon Lehnbeuter StarGen (SAR422459) UshStat...
BioCentury | Feb 24, 2014
Company News

Oxford BioMedica, Sanofi deal

...The companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and...
...amendment, Oxford BioMedica said it is eligible for development and commercialization milestones, plus royalties, for StarGen...
...a worldwide license to develop and commercialize four preclinical compounds to treat ocular diseases, including StarGen...
BioCentury | Oct 28, 2013
Clinical News

StarGen: Phase I/IIa ongoing

...Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Oct 28, 2013
Clinical News

UshStat: Phase I/IIa ongoing

...Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Oct 28, 2013
Clinical News

RetinoStat: Phase I ongoing

...Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Jun 10, 2013
Clinical News

RetinoStat: Phase I suspended enrollment

...BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Jun 10, 2013
Clinical News

StarGen: Phase I/IIa suspended enrollment

...BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Jun 10, 2013
Clinical News

UshStat: Phase I/IIa suspended enrollment

...BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...Phase I/IIa trial to treat Stargardt's disease. The trial is evaluating 3 dose levels of StarGen...
BioCentury | Dec 10, 2012
Clinical News

StarGen: Interim Phase I/IIa data

...disease in the first cohort of an open-label, dose-escalation, international Phase I/IIa trial showing that StarGen...
...to the third cohort of the trial. The trial is evaluating 3 dose levels of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
BioCentury | Aug 13, 2012
Clinical News

StarGen: Phase I/IIa started

...dose-escalation, international Phase I/IIa trial of StarGen. The trial is evaluating 3 dose levels of StarGen...
...its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's StarGen...
...July 9, 2012). Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: StarGen...
Items per page:
1 - 10 of 15